Table 2.
Area of dysfunction (specific measure) | Alleviated by succimer? |
---|---|
High-Pb group | |
Impaired learning ability | |
Visual discrimination task: rate of decline of percent errors | N |
Attention task 1: rate of decline of percent premature responses | I |
Impaired Inhibitory control | |
Attention task 1: increased percent premature responses in final block of sessions | N |
Sustained attention task: percent premature responses (throughout all sessions) | N |
Increased disruption following errors (impaired arousal regulation) | |
Attention task 1: increased alcove latency in first block of sessions | Y |
Attention task 1: increased response latency in first block of sessions | Y |
Sustained attention task: increased omission errors on post-error trials | Y |
Lapses in attention (pattern of group differences as a function of cue duration) | I |
Early session increase in omission errors (transition problems → attention dysfunction) | I |
Mod-Pb Group | |
Impaired learning ability | |
Visual discrimination task: rate of decline of percent errors | Y |
Attention task 1: rate of decline of percent premature responses | Y |
Succimer-only group | |
Impaired learning ability: visual discrimination task (rate of decline of percent errors) | |
Attentional dysfunction: attention task 1 (increased percent inaccurate responses) | |
Lapses in attention (pattern of effects as a function of cue duration) | |
Sustained attention task | |
Selective attention task | |
Impaired arousal regulation | |
Selective attention task: group differences greatest on post-error distraction trials | |
Higher rate of errors on nondistraction trials in selective attention task than in baseline task |
For the High-Pb and Mod-Pb groups, the right-hand column indicates whether succimer treatment significantly alleviated the dysfunction (Y), did not significantly alleviate dysfunction (N), or produced a level of performance that was intermediate (I; i.e., not significantly different from either the control group or their vehicle-treated counterparts).